Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
1-Minute Consult

How can I select the right thyroid hormone formulation for my patient with hypothyroidism?

Lea El Hage, MD and Vinni Makin, MBBS, MD
Cleveland Clinic Journal of Medicine December 2025, 92 (12) 745-747; DOI: https://doi.org/10.3949/ccjm.92a.25042
Lea El Hage
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elhagel{at}ccf.org
  • Find this author on Cleveland Clinic
Vinni Makin
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 35-year-old woman with hypothyroidism is referred to our clinic for treatment. She was diagnosed recently with celiac disease and is lactose intolerant. A vegetarian, she prefers to avoid medications containing animal-derived ingredients. The patient asks if there is a formulation of thyroid hormone that will fit her specific needs and preferences.

It is not uncommon for patients to ask about specific formulations of thyroid hormone based on their preferences and intolerances. Table 1 lists available thyroid hormone formulations—which include options for patients with dietary restrictions, intolerances, or preferences—and summarizes the differences between them, including approximate cost and insurance coverage.1–3 Knowing the inert ingredients and other features of the available formulations can provide a starting point for individualizing thyroid hormone therapy for patients who have concerns about specific formulations or continue to have symptoms despite achieving a normal thyroid-stimulating hormone level. Other factors that may affect a patient’s thyroid hormone–replacement treatment plan are variations among formulations in dose, dosing frequency, and bioavailability; patient age; malabsorption; and coexisting conditions.

View this table:
  • View inline
  • View popup
TABLE 1

Features of available thyroid formulations

LEVOTHYROXINE: ONE THYROID MEDICATION DOES NOT FIT ALL

Levothyroxine, a synthetic form of thyroxine (T4), is one of the most commonly prescribed drugs in noninstitutionalized US adults age 20 and older, according to an analysis using the National Health and Nutrition Examination Survey database, 2011–2012.4 A retrospective, cross-sectional analysis of pharmacy claims including more than 100 million individuals with varied insurance coverage showed that 73.6% of pharmacy-filled thyroid hormone prescriptions were for generic levothyroxine, 23.4% for brand-name levothyroxine, 1.7% for desiccated thyroid extract, and 1.0% for generic liothyronine, a synthetic form of triiodothyronine (T3).5

Despite the widespread use of levothyroxine, it may not always be appropriate for a patient for the reasons outlined above. The sections that follow offer further guidance on drug selection.

SEEKING THE MOST SUITABLE FORMULATION: SOME PRACTICAL TIPS

T4 considerations

When switching a patient’s thyroid medication (eg, patients with fluctuating absorption or who need tight control of thyroid-stimulating hormone such as those with thyroid cancer), clinicians must keep in mind that variations in dose and bioavailability in T4 formulations may cause fluctuations in thyroid-stimulating hormone levels; however, studies of this effect have shown conflicting results.6–8 The American Thyroid Association guidelines9 recommend reevaluating serum thyroid-stimulating hormone levels if switching levothyroxine formulations, but cite this as a weak recommendation with low-quality evidence.

It is recommended that T4 medications be stored away from direct moisture and heat at a temperature between 68°F and 77°F (20°C–25°C).9 This recommendation may be difficult to follow for individuals who travel frequently. Euthyrox (levothyroxine) is blister packed and may have longer preserved potency compared with bottle-packed or amber vials.10

T3 considerations

T3 is the active form of thyroid hormone. Prohormone T4 is converted to T3 regardless of whether the patient has thyroid disease or the thyroid gland is present. Because a patient’s T3 level increases rapidly after intake and then declines, those taking T3 medications may need multiple doses (up to 3 times a day). This dosing schedule may be difficult for patients to follow, and once-daily dosing might not provide physiologic replacement.11 T4, however, has a half-life of 1 week, so it is dosed daily and reaches a steady state after a month.

Desiccated thyroid extract and combination T4 and T3

Desiccated thyroid extract, thyroid hormone extracted from porcine thyroid gland, contains both T4 and T3; the T4:T3 ratio differs from that in humans, with desiccated thyroid extract having a significantly higher T3 component. For patients who avoid pork-derived products, formulations that contain thyroid hormone extracted from bovine thyroid glands can be purchased online. Neither bovine nor porcine formulations are approved by the US Food and Drug Administration. Also, bovine thyroid extract is not standardized, its dosing may not be consistent, and it is not available in retail pharmacies. Porcine thyroid extract may be inconsistent between batches but is more standardized than bovine extract and is available in retail pharmacies.

If a patient’s hypothyroid symptoms persist with T4 monotherapy despite achieving an optimal thyroid-stimulating hormone level, combination therapy with levothyroxine and liothyronine (T3) or switching to desiccated thyroid extract can be considered.11–15 Patients receiving T4 who have a presumed genetic polymorphism that leads to inadequate deiodinase function will need the addition of T3 or treatment with desiccated thyroid extract.16

Research data are sparse and controversial and professional society guidelines are ambiguous and open to wide interpretation, but we advise caution when considering T3 or desiccated thyroid extract for patients older than 65; those with religious preferences that conflict with formulations that have porcine or bovine extracts; and those with unstable cardiovascular disease, active malignancy, or uncontrolled psychiatric disease.17,18

T3 does not cross the placenta and should not be used during pregnancy.17 Pregnant patients taking T3 or desiccated thyroid extract should be switched to T4, and the T4 dose should be increased by 30%, which can be achieved by taking 2 extra tablets per week.

Patients with dietary requirements and preferences

Formulations that contain gelatin, which is made from animal collagen, may have limited use in vegetarians, vegans, or individuals with religious preferences. Some formulations also contain lactose, gluten, or dye (Table 1). These formulations should be avoided in those with certain medical conditions, allergies, intolerances, or sensitivities.

Patients with absorption problems

Patients who have absorption challenges, such as those who have undergone gastrointestinal surgeries or have gastrointestinal diseases, may need higher T4 doses. If absorption difficulty continues, other options include taking the T4 crushed, switching to liquid Tirosint (levothyroxine), adding T3, or switching to desiccated thyroid extract.2 If these changes have no effect on absorption problems, then weekly or biweekly intramuscular levothyroxine injections can be considered.19

THE BOTTOM LINE

Levothyroxine is the most commonly prescribed thyroid hormone medication, but it may not be appropriate for certain patients. For our patient, we recommended Levoxyl, a brand of levothyroxine sodium, to meet her need for a formulation free from gluten (celiac disease), gelatin or animal extract (vegetarian), and lactose (lactose intolerance).

DISCLOSURES

Dr. Makin has disclosed teaching and speaking for Bayer and being an advisor or review panel participant for Willow Laboratories. Dr. El Hage reports no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2025 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Benvenga S
    . Liquid and softgel capsules of l-thyroxine results lower serum thyrotropin levels more than tablet formulations in hypothyroid patients. J Clin Transl Endocrinol 2019; 18:100204. doi:10.1016/j.jcte.2019.100204
    OpenUrlCrossRefPubMed
  2. ↵
    1. Virili C,
    2. Antonelli A,
    3. Santaguida MG,
    4. Benvenga S,
    5. Centanni M
    . Gastrointestinal malabsorption of thyroxine. Endocr Rev 2019; 40(1):118–136. doi:10.1210/er.2018-00168
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kahaly GJ
    1. Lipp HP
    . Administration and pharmacokinetics of levothyroxine. In: Kahaly GJ, ed. 70 Years of Levothyroxine. Cham, Switzerland: Springer; 2021:13–22.
  4. ↵
    1. Kantor ED,
    2. Rehm CD,
    3. Haas JS,
    4. Chan AT,
    5. Giovannucci EL
    . Trends in prescription drug use among adults in the United States from 1999– 2012. JAMA 2015; 314(17):1818–1831. doi:10.1001/jama.2015.13766
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ross JS,
    2. Rohde S,
    3. Sangaralingham L, et al
    . Generic and brand-name thyroid hormone drug use among commercially insured and Medicare beneficiaries, 2007 through 2016. J Clin Endocrinol Metab 2019; 104(6):2305–2314. doi:10.1210/jc.2018-02197
    OpenUrlCrossRefPubMed
  6. ↵
    1. Wang L,
    2. Chen YJ,
    3. Grabner M, et al
    . Comparative effectiveness of persistent use of a name-brand levothyroxine (Synthroid®) vs. persistent use of generic levothyroxine on TSH goal achievement: a retrospective study among patients with hypothyroidism in a managed care setting. Adv Ther 2022; 39(1):779–795. doi:10.1007/s12325-021-01969-3
    OpenUrlCrossRefPubMed
    1. Hennessey JV,
    2. Espaillat R,
    3. Duan Y,
    4. Soni-Brahmbhatt S,
    5. Lage MJ,
    6. Singer P
    . The association between switching from Synthroid® and clinical outcomes: US evidence from a retrospective database analysis. Adv Ther 2021; 38(1):337–349. doi:10.1007/s12325-020-01537-1
    OpenUrlCrossRefPubMed
  7. ↵
    1. Brito JP,
    2. Deng Y,
    3. Ross JS, et al
    . Association between generic-to-generic levothyroxine switching and thyrotropin levels among US adults. JAMA Intern Med 2022; 182(4):418–425. doi:10.1001/jamainternmed.2022.0045
    OpenUrlCrossRefPubMed
  8. ↵
    1. Jonklaas J,
    2. Bianco AC,
    3. Bauer AJ, et al
    . Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 2014; 24(12):1670–1751. doi:10.1089/thy.2014.0028
    OpenUrlCrossRefPubMed
  9. ↵
    1. Chun J
    . Stability of levothyroxine tablets in blister packaging versus bottles and vials under simulated in-use conditions. AAPS Open 2022; 8:15.
    OpenUrl
  10. ↵
    1. Jonklaas J,
    2. Bianco AC,
    3. Cappola AR, et al
    . Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid 2021; 31(2):156–182. doi:10.1089/thy.2020.0720
    OpenUrlCrossRefPubMed
    1. Salvatore D,
    2. Porcelli T,
    3. Ettleson MD,
    4. Bianco AC
    . The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol 2022; 10(5):366–372. doi:10.1016/S2213-8587(22)00004-3
    OpenUrlCrossRefPubMed
    1. Ettleson MD,
    2. Bianco AC
    . Individualized therapy for hypothyroidism: is T4 enough for everyone? J Clin Endocrinol Metab 2020; 105(9):e3090–e3104. doi:10.1210/clinem/dgaa430
    OpenUrlCrossRefPubMed
    1. Wartofsky L
    . Combination L-T3 and L-T4 therapy for hypothyroidism. Curr Opin Endocrinol Diabetes Obes 2013; 20(5):460–466. doi:10.1097/01.med.0000432611.03732.49
    OpenUrlCrossRefPubMed
  11. ↵
    1. Riis KR,
    2. Larsen CB,
    3. Bonnema SJ
    . Potential risks and benefits of desiccated thyroid extract for the treatment of hypothyroidism: a systematic review. Thyroid 2024; 34(6):687–701. doi:10.1089/thy.2023.0649
    OpenUrlCrossRefPubMed
  12. ↵
    1. Castagna MG,
    2. Dentice M,
    3. Cantara S, et al
    . DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J Clin Endocrinol Metab 2017; 102(5):1623–1630. doi:10.1210/jc.2016-2587
    OpenUrlCrossRefPubMed
  13. ↵
    1. Alexander EK,
    2. Pearce EN,
    3. Brent GA, et al
    . 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27(3):315–389. doi:10.1089/thy.2016.0457
    OpenUrlCrossRefPubMed
  14. ↵
    1. Yi W,
    2. Kim BH,
    3. Kim M, et al
    . Heart failure and stroke risks in users of liothyronine with or without levothyroxine compared with levothyroxine alone: a propensity score-matched analysis. Thyroid 2022; 32(7):764–771. doi:10.1089/thy.2021.0634
    OpenUrlCrossRefPubMed
  15. ↵
    1. Chaudhury N,
    2. Crasto W,
    3. Saravanan P,
    4. Patel V
    . Intramuscular and subcutaneous levothyroxine: success in treating refractory hypothyroidism. Eur Thyroid J 2025; 14(2):e250012. doi:10.1530/ETJ-25-0012
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 92 (12)
Cleveland Clinic Journal of Medicine
Vol. 92, Issue 12
1 Dec 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How can I select the right thyroid hormone formulation for my patient with hypothyroidism?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
How can I select the right thyroid hormone formulation for my patient with hypothyroidism?
Lea El Hage, Vinni Makin
Cleveland Clinic Journal of Medicine Dec 2025, 92 (12) 745-747; DOI: 10.3949/ccjm.92a.25042

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
How can I select the right thyroid hormone formulation for my patient with hypothyroidism?
Lea El Hage, Vinni Makin
Cleveland Clinic Journal of Medicine Dec 2025, 92 (12) 745-747; DOI: 10.3949/ccjm.92a.25042
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • LEVOTHYROXINE: ONE THYROID MEDICATION DOES NOT FIT ALL
    • SEEKING THE MOST SUITABLE FORMULATION: SOME PRACTICAL TIPS
    • THE BOTTOM LINE
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Should I consider low-dose rivaroxaban (2.5 mg) for my patient with peripheral artery disease?
  • How should I incorporate emergency contraception counseling into my practice?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Endocrinology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire